Cymabay Therapeutics Inc CBAY:NASDAQ

Last Price$1.90NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change0.00(0.00%)
Bid (Size)N/A (N/A)
Ask (Size)N/A (N/A)
Day Low / High$1.88 - 1.94
Volume666.9 K

View Biotechnology IndustryPeer Comparison as of 05/18/2022


Cymabay Therapeutics Inc ( NASDAQ )

Price: $1.90
Change: 0.00 (0.00%)
Volume: 666.9 K
4:00PM ET 5/18/2022

DarioHealth Corp ( NASDAQ )

Price: $6.45
Change: -0.74 (10.29%)
Volume: 240.00
4:00PM ET 5/18/2022

Armata Pharmaceuticals Inc ( NYSE MKT LLC )

Price: $4.31
Change: -0.32 (6.91%)
Volume: 22.5 K
8:00PM ET 5/18/2022

Harvard Bioscience Inc ( NASDAQ )

Price: $3.65
Change: -0.09 (2.41%)
Volume: 166.6 K
4:00PM ET 5/18/2022

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $2.46
Change: -0.18 (6.82%)
Volume: 629.7 K
4:00PM ET 5/18/2022

Read more news Recent News

B. Riley Lowers Cymabay Therapeutics' Price Target to $8 from $10 to Account for Slightly Delayed Launch Timeline, Higher Cost of Capital; Keeps Buy Rating
10:10AM ET 5/18/2022 MT Newswires

Cymabay Therapeutics (CBAY) has an average rating of buy and price targets ranging from $7 to $14, according to analysts polled by Capital IQ. (MT...

HC Wainwright Lowers Cymabay Therapeutics's Price Target to $10 From $12, Maintains Buy Rating
9:57AM ET 5/16/2022 MT Newswires

Cymabay Therapeutics (CBAY) has an average rating of buy and price targets ranging from $7 to $14, according to analysts polled by Capital IQ. (MT...

Cymabay Therapeutics Q1 Loss Widens, Sees Enough Funds Through 2023 -- Stock Rises 7% After-Hours
5:07PM ET 5/12/2022 MT Newswires

Cymabay Therapeutics (CBAY) said Thursday its net loss widened to $0.32 per share in Q1 from $0.25 per share a year earlier. Analysts polled by Capital IQ...

Earnings Reaction History: CymaBay Therapeutics Inc, 60.0% Follow-Through Indicator, 17.9% Sensitive
1:07PM ET 5/12/2022 MT Newswires

Expected Earnings Release: 05/12/2022, After-hours Avg. Extended-Hours Dollar Volume: $3,063,652 CymaBay Therapeutics Inc (CBAY) is due to issue its...

Company Profile

Business DescriptionCymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. View company web site for more details
Address7575 Gateway Boulevard
Newark, California 94560
Number of Employees43
Recent SEC Filing05/12/202210-Q
President, Chief Executive Officer & DirectorSujal Shah
Vice President-FinanceDaniel Menold
Chief Scientific Officer & Senior Vice PresidentCharles A. McWherter
Chief Medical OfficerDennis D. Kim

Company Highlights

Price Open$1.88
Previous Close$1.90
52 Week Range$1.67 - 5.06
Market Capitalization$160.9 M
Shares Outstanding84.7 M
SectorHealth Technology
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.26
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-79.17%

Analyst Ratings as of 03/25/2022

Consensus RecommendationConsensus Icon
Powered by Factset